Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...

The UK's medicines regulator has launched a study to investigate the impact of these drugs following reports of people dying ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Proponents say direct-to-consumer sales by drugmakers cut out intermediaries that add needlessly to prices. Detractors see ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Due to popularity of the medications, GLP-1s were in short supply up until recently. Obesity is a common issue among ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Hims & Hers stands out for personalized, compounded medications and consistent margin expansion but faces rising risks tied ...

Hundreds of people have reported problems with their pancreas linked to taking weight loss and diabetes jabs, prompting ...

Anthropic's Scott White explains how AI agents evolved from chatbots to autonomous workers at VentureBeat Transform 2025, cutting enterprise tasks from weeks to minutes.

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...